Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRP for Genitourinary Syndrome of Menopause in Breast Cancer Survivors
NCT04535323Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Sep 2020
- Primary completion
- Jan 2024
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous platelet-rich plasma in genitourinary syndrome of menopause (GSM), sponsored by Mayo Clinic. Primary endpoints: Incidence of adverse events at 2 weeks and Tolerability of planned injection regimen with pain scores at 6 months. Started Sep 2020; status: completed.
02
Drugs
autologous platelet-rich plasma
03
Conditions
genitourinary syndrome of menopause (GSM)
Beyond the preview
Go deeper on NCT04535323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04535323.